GA
IMMU

Geneva Advisors’s Immunomedics Inc IMMU Stock Holding History

Geneva Advisors’s Portfolio IMMU Stock Details IMMU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$279K Buy
31,635
+200
+0.6% +$1.4K ﹤0.01% 612
2017
Q1 		$203K Sell
31,435
-2,500
-7% -$12.7K ﹤0.01% 679
2016
Q4 		$125K Hold
33,935
– – ﹤0.01% 713
2016
Q3 		$110K Hold
33,935
– – ﹤0.01% 690
2016
Q2 		$79K Sell
33,935
-7,500
-18% -$25.1K ﹤0.01% 655
2016
Q1 		$104K Sell
41,435
-120
-0.3% -$270 ﹤0.01% 643
2015
Q4 		$128K Buy
+41,555
New +$116K ﹤0.01% 597

Other funds holding IMMU

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Geneva Advisors's IMMU Position: Q2 2017 in Review

Geneva Advisors increased its Immunomedics Inc (IMMU) stake by 0.64% in Q2 2017, buying an estimated $1.4K and bringing the position to 31,635 shares worth $279K. The position accounts for ﹤0.01% of the portfolio, ranked #612.

Geneva Advisors first reported a position in IMMU in Q4 2015 and has held it in 7 quarters since. 130 funds tracked by Wall St. Rank hold IMMU as of Q2 2017.

  • Geneva Advisors held 31,635 shares of Immunomedics Inc worth $279K as of Q2 2017.
  • Geneva Advisors bought 200 Immunomedics Inc shares in Q2 2017, an estimated $1.4K.
  • Immunomedics Inc made up ﹤0.01% of Geneva Advisors's portfolio in Q2 2017, its #612 holding.
  • Geneva Advisors first reported a position in Immunomedics Inc in Q4 2015 and has held it in 7 quarters since.
  • 130 funds tracked by Wall St. Rank held Immunomedics Inc as of Q2 2017.

Based on Geneva Advisors's 13F filing for Q2 2017, filed 7 Aug 2017.